Literature DB >> 3513009

Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy.

B Feldt-Rasmussen, E R Mathiesen, L Hegedüs, T Deckert.   

Abstract

Thirty-six patients with insulin-dependent diabetes mellitus who had Albustix-negative urine but elevated urinary albumin excretion (30 to 300 mg per 24 hours) were matched in pairs according to their urinary albumin level, blood glycosylated hemoglobin level, and sex and assigned randomly to either unchanged conventional treatment or continuous insulin infusion. During the next 12 months a significant improvement in glycemic control was observed in the insulin-infusion group, with a reduction in the mean glycosylated hemoglobin level from 9.5 to 7.3 percent. There was no change in the control group (9.3 to 9.2 percent). No significant change in albumin excretion was observed in either group. The mean blood pressure increased slightly in both groups (from 98 to 101 mm Hg in the insulin-infusion group and from 98 to 103 mm Hg in the control group). Kidney size was significantly reduced in all patients during insulin infusion, but no consistent change was observed in the control group. No significant change was observed in the glomerular filtration rate. Our data suggest that the pathologic processes causing microalbuminuria in early renal disease are not reversed during 12 months of strict metabolic control.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513009     DOI: 10.1056/NEJM198603133141101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

1.  Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies.

Authors:  B Feldt-Rasmussen; E R Mathiesen; T Jensen; T Lauritzen; T Deckert
Journal:  Diabetologia       Date:  1991-03       Impact factor: 10.122

Review 2.  To bridge science and patient care in diabetes.

Authors:  M Berger
Journal:  Diabetologia       Date:  1996-07       Impact factor: 10.122

Review 3.  ACE inhibitors in the prevention and therapy of diabetic nephropathy. What is their role?

Authors:  C C Kelleher
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

4.  'Microalbuminuria' in type I (insulin-dependent) diabetic patients with and without retinopathy.

Authors:  R Miccoli; O Giampietro; G Penno; G Odello; R Anichini; A Bertolotto; L Cruschelli; S Bertoli; R Navalesi
Journal:  Acta Diabetol Lat       Date:  1989 Apr-Jun

5.  Effect of eicosapentaenoic acid ethyl ester on proteinuria of streptozotocin-induced diabetes mellitus in rats.

Authors:  M Fujikawa; K Yamazaki; S Sawazaki; H Taki; M Kaneda; M Urakaze; T Hamazaki; S Yano; T Fujita
Journal:  Lipids       Date:  1989-09       Impact factor: 1.880

6.  Prevalence of microalbuminuria in children with type 1 (insulin-dependent) diabetes mellitus.

Authors:  E R Mathiesen; N Saurbrey; E Hommel; H H Parving
Journal:  Diabetologia       Date:  1986-09       Impact factor: 10.122

7.  Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria.

Authors:  B Feldt-Rasmussen
Journal:  Diabetologia       Date:  1986-05       Impact factor: 10.122

8.  Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus.

Authors:  B Feldt-Rasmussen; E R Mathiesen; T Deckert; J Giese; N J Christensen; L Bent-Hansen; M D Nielsen
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

9.  Effects of captopril on diabetic nephropathy in hypertensive women.

Authors:  L Gonzalez-Sicilia de Llamas; A Garcia Alberola; M Lafuente Lopez-Herrera; T Fuente Jimenez; J Fernandez Pardo; J Hernandez Cascales
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 10.  Cost-effective strategies in the prevention of diabetic nephropathy.

Authors:  Jonathan D Rippin; Anthony H Barnett; Stephen C Bain
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.